Individuals with any of the following conditions should consult with their healthcare provider before use and may not be eligible for treatment: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Known hypersensitivity to GLP-1 or GLP-1/GIP medications or any formulation components, including additives such as vitamin B12 or cobalt Pregnancy or plans to become pregnant (therapy should be discontinued at least two months prior to planned pregnancy) Diabetic ketoacidosis (DKA) or type 1 diabetes Severe gastrointestinal disease (including gastroparesis or active inflammatory bowel disease) Severe cardiovascular disease (including unstable coronary artery disease or heart failure) Recent bariatric or gastrointestinal surgery within the past six months Active cancer currently undergoing chemotherapy or radiation treatment This list is not comprehensive
Genetic engineering and human enhancement technologies could lead to medical breakthroughs that cure diseases and improve quality of life, and ethical frameworks can be developed to guide their use
This makes it necessary to develop sustained or controlled release transdermal patches under second aspect
Work with your healthcare provider to find the treatment that works best for you based on your situation
Painter MM, Johnston TS, Lundgreen KA, Santos J, Qin JS, Goel RR, et al
Bioorg Med Chem Lett 20 , 260265, (2010)
